Oxaliplatin

**Oxaliplatin** is not a molecular target, receptor, enzyme, or protein, but rather a **platinum-based small molecule chemotherapy drug** used primarily to treat colorectal cancer. It acts as an antineoplastic agent by forming DNA crosslinks after non-enzymatic activation; these crosslinks interfere with DNA replication and transcription, resulting in cell death. Oxaliplatin is distinct from cisplatin and carboplatin due to its structure, where the platinum is complexed with 1,2-diaminocyclohexane and an oxalate ligand, conferring different pharmacological and safety properties[1][2][3][4][5][7]. **Additional context:** - The entry “Oxaliplatin” refers to a drug, not a biological target. As such, there are no protein/gene aliases, molecular classifications, biological functions, or interacting drugs in the sense used for molecular targets. - If you are interested in oxaliplatin’s *targets*, these are generally **DNA (specifically guanine N7 positions in DNA)** where the agent forms crosslinks, but “Oxaliplatin” itself is not a receptor or target[1][4]. - Mark this entry as **is_incorrect: true** for a molecular target database, since it refers to a *drug*, not a *target*.

Other names

L-OHPOxalatoplatinumOxalatoplatinoxaliplatineoxaliplatinooxaliplatinumXaliplatinJM-83NSC-266046RP-54780SR-96669